European heart journal
-
European heart journal · Dec 2015
Randomized Controlled Trial Multicenter Study Comparative StudyA randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
Theoretically, bioresorbable vascular scaffolds (BVSs) may provide superior long-term results compared with permanent metallic drug-eluting stents (DESs). However, whether BVSs are as safe and effective as metallic DESs prior to complete bioresorption is unknown. ⋯ ClinicalTrials.gov, number NCT01844284.
-
European heart journal · Dec 2015
Randomized Controlled Trial Multicenter StudyThe ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations. ⋯ The five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support clinical decision making.
-
European heart journal · Dec 2015
Randomized Controlled Trial Multicenter StudyImpact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
The influence of reticulated platelets (RPs) on platelet inhibition by ticagrelor when compared with prasugrel is unknown. We aimed to determine the influence of RPs on adenosine diphosphate- (ADP-) induced platelet aggregation in patients with acute coronary syndrome who were randomly assigned to receive either ticagrelor or prasugrel for P2Y12 receptor inhibition. ⋯ Reticulated platelets show a greater impact on platelet reactivity in response to prasugrel when compared with ticagrelor.
-
European heart journal · Aug 2015
Randomized Controlled Trial Multicenter Study Comparative StudyMarfan Sartan: a randomized, double-blind, placebo-controlled trial.
To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS). ⋯ Losartan was able to decrease blood pressure in patients with MFS but not to limit aortic dilatation during a 3-year period in patients >10 years old. β-Blocker therapy alone should therefore remain the standard first line therapy in these patients.
-
European heart journal · Aug 2015
Randomized Controlled Trial Multicenter Study Comparative StudyEffect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death. ⋯ https://clinicaltrials.gov/, NCT01035255.